David Aaron  Lehman net worth and biography

David Lehman Biography and Net Worth

General Counsel of Pulmonx
David brings over 30 years of experience as an in-house attorney to Pulmonx. Prior to joining Pulmonx, David was Executive Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary at Intersect ENT, where he created and managed the legal and compliance function for the ENT medical technology company. Prior to Intersect ENT, he was with Thoratec Corporation, a global leader in medical technology addressing advanced-stage heart failure, as Senior Vice President, General Counsel and Secretary until Thoratec’s sale to St. Jude Medical in 2015. Prior to that, he served as Vice President and General Counsel at Brigade Corporation, a business process outsourcing company. He previously held positions in the legal departments of Bio-Rad Laboratories, Inc., a life science research and clinical diagnostics company, and Mitsubishi International Corporation, a Japanese trading company, in their New York and Tokyo offices. David began his career as an associate attorney at the law firm of Hall, Dickler, Kent, Friedman & Wood in New York. David holds a B.A. in political science from The University of California, San Diego and a J.D. from Cornell University Law School.

What is David Aaron Lehman's net worth?

The estimated net worth of David Aaron Lehman is at least $1.35 million as of March 1st, 2024. Mr. Lehman owns 145,488 shares of Pulmonx stock worth more than $1,348,674 as of March 29th. This net worth estimate does not reflect any other investments that Mr. Lehman may own. Additionally, Mr. Lehman receives an annual salary of $571,590.00 as General Counsel at Pulmonx. Learn More about David Aaron Lehman's net worth.

How old is David Aaron Lehman?

Mr. Lehman is currently 63 years old. There are 5 older executives and no younger executives at Pulmonx. Learn More on David Aaron Lehman's age.

What is David Aaron Lehman's salary?

As the General Counsel of Pulmonx Co., Mr. Lehman earns $571,590.00 per year. The highest earning executive at Pulmonx is Mr. Glendon E. French, CEO, President & Director, who commands a salary of $892,290.00 per year. Learn More on David Aaron Lehman's salary.

How do I contact David Aaron Lehman?

The corporate mailing address for Mr. Lehman and other Pulmonx executives is , , . Pulmonx can also be reached via phone at 1-650-364-0400 and via email at [email protected]. Learn More on David Aaron Lehman's contact information.

Has David Aaron Lehman been buying or selling shares of Pulmonx?

During the past quarter, David Aaron Lehman has sold $39,420.06 in shares of Pulmonx stock. Most recently, David Aaron Lehman sold 4,351 shares of the business's stock in a transaction on Friday, March 1st. The shares were sold at an average price of $9.06, for a transaction totalling $39,420.06. Following the completion of the sale, the general counsel now directly owns 145,488 shares of the company's stock, valued at $1,318,121.28. Learn More on David Aaron Lehman's trading history.

Who are Pulmonx's active insiders?

Pulmonx's insider roster includes Daniel Florin (Director), Glendon French, III (CEO), David Lehman (General Counsel), Geoffrey Rose (Insider), and Derrick Sung (CFO). Learn More on Pulmonx's active insiders.

Are insiders buying or selling shares of Pulmonx?

In the last twelve months, insiders at the sold shares 29 times. They sold a total of 138,984 shares worth more than $1,628,116.18. The most recent insider tranaction occured on March, 22nd when insider Geoffrey Beran Rose sold 1,184 shares worth more than $11,082.24. Insiders at Pulmonx own 5.7% of the company. Learn More about insider trades at Pulmonx.

Information on this page was last updated on 3/22/2024.

David Aaron Lehman Insider Trading History at Pulmonx

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/1/2024Sell4,351$9.06$39,420.06145,488View SEC Filing Icon  
12/1/2023Sell3,809$10.34$39,385.06149,839View SEC Filing Icon  
9/1/2023Sell3,772$10.01$37,757.72153,648View SEC Filing Icon  
6/1/2023Sell3,776$11.48$43,348.48157,420View SEC Filing Icon  
12/1/2022Sell1,069$5.93$6,339.1744,160View SEC Filing Icon  
6/1/2022Sell1,065$18.05$19,223.2546,311View SEC Filing Icon  
3/1/2022Sell458$25.91$11,866.78View SEC Filing Icon  
12/1/2021Sell383$32.73$12,535.59View SEC Filing Icon  
See Full Table

David Aaron Lehman Buying and Selling Activity at Pulmonx

This chart shows David Aaron Lehman's buying and selling at Pulmonx by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Pulmonx Company Overview

Pulmonx logo
Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Read More

Today's Range

Now: $9.27
Low: $9.12
High: $9.46

50 Day Range

MA: $11.58
Low: $8.71
High: $14.65

2 Week Range

Now: $9.27
Low: $7.75
High: $14.84

Volume

943,295 shs

Average Volume

489,593 shs

Market Capitalization

$357.27 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.59